Literature DB >> 16236745

Trastuzumab in the treatment of breast cancer.

Gabriel N Hortobagyi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16236745     DOI： 10.1056/NEJMe058196

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  72 in total

1.  Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.

Authors:  Ralf Kircheis; Nicole Halanek; Iris Koller; Wolfgang Jost; Manfred Schuster; Gilbert Gorr; Klaus Hajszan; Andreas Nechansky
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 2.  Personalized cancer medicine and the future of pathology.

Authors:  H Moch; P R Blank; M Dietel; G Elmberger; K M Kerr; J Palacios; F Penault-Llorca; G Rossi; T D Szucs
Journal:  Virchows Arch       Date:  2011-12-06       Impact factor: 4.064

Review 3.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

4.  Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays.

Authors:  Antoine-Emmanuel Saliba; Laure Saias; Eleni Psychari; Nicolas Minc; Damien Simon; François-Clément Bidard; Claire Mathiot; Jean-Yves Pierga; Vincent Fraisier; Jean Salamero; Véronique Saada; Françoise Farace; Philippe Vielh; Laurent Malaquin; Jean-Louis Viovy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

5.  Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.

Authors:  Ke Liang; Francisco J Esteva; Constance Albarracin; Katherine Stemke-Hale; Yang Lu; Giampaolo Bianchini; Ching-Yi Yang; Yong Li; Xinqun Li; Chun-Te Chen; Gordon B Mills; Gabriel N Hortobagyi; John Mendelsohn; Mien-Chie Hung; Zhen Fan
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

6.  Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.

Authors:  Sara Rodriguez-Acebes; Ian Proctor; Marco Loddo; Alex Wollenschlaeger; Mohammed Rashid; Mary Falzon; A Toby Prevost; Richard Sainsbury; Kai Stoeber; Gareth H Williams
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 7.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

8.  Adjuvant trastuzumab for breast cancer.

Authors:  Rebecca Dent; Mark Clemons
Journal:  BMJ       Date:  2005-11-05

Review 9.  Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management.

Authors:  Jean Domercant; Nichole Polin; Eiman Jahangir
Journal:  Ochsner J       Date:  2016

10.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.